New Research

New research from the CWMH.

New Research from the CWMH: Both Estradiol and Venlafaxine Improve Quality of Life in Perimenopausal Women with Hot Flashes

In healthy perimenopausal women with hot flashes, treatment with both estradiol and venlafaxine resulted in significantly greater improvement in quality of life, as compared to placebo. Estradiol had beneficial treatment effects on all domains of the [...]

New Research from the CWMH: CBT to Reduce Risk of Relapse in Women Attempting to Discontinue Antidepressants

Pregnancy is a time of risk for women with histories of major depression. In a study where 201 women with histories of recurrent depression were followed prospectively through pregnancy, 43% experienced a relapse of major depression during pregnancy. Relapse rates were highest in the group of women who elected to discontinue antidepressant treatment proximate to conception (68% as compared to 26% in the group of women who maintained antidepressant treatment).

New Research from the CWMH: Venlafaxine As Effective As Estradiol for Hot Flashes

Various selective serotonin reuptake inhibitors (SSRIs), including citalopram (Celexa), escitalopram (Lexapro) and paroxetine (Paxil), have been shown to be effective for the treatment of menopausal vasomotor symptoms (VMS). Other studies have supported the efficacy of the serotonin–norepinephrine reuptake inhibitors (SNRIs) duloxetine (Cymbalta) and venlafaxine (Effexor). The FDA recently approved a 7.5-mg formulation of paroxetine (marketed as Brisdelle) as the first non-hormonal treatment of hot flashes.

Research from the CWMH: Are Omega-3 Fatty Acids Effective for Menopausal Vasomotor Symptoms?

Approximately seventy percent of all women experience hot flashes and/or night sweats during the menopause transition (Stearns et al, 2002).  Until recently, estrogen therapy was the treatment of choice for most women who sought treatment for hot flashes, but today many women are pursuing non-hormonal treatments, including over-the-counter complementary and alternative medicines (CAMs) for the treatment of these symptoms. 

Prevalence and Trends in the Use of Antipsychotic Medications during Pregnancy

Since their introduction in the 1990s, atypical (second-generation) antipsychotics have replaced typical (first generation) antipsychotics as the first-line treatment for schizophrenia and related psychotic disorders. These drugs are widely used by reproductive age women across many other disease states including bipolar disorder, major depression and anxiety disorders as either primary or adjunctive treatments.